Skip to main content

Advertisement

SpringerLink
Log in

MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Bevacizumab is a therapeutic drug used in treatment of recurrent glioblastoma to inhibit angiogenesis. Treatment response is often monitored through the use of perfusion MRI measures of cerebral blood volume, flow, and other pharmacokinetic parameters; however, most methods for deriving these perfusion parameters can produce errors depending on bolus kinetics. Recently, a number of new methods have been developed to overcome these challenges. In the current study we examine cerebral blood volume and blood flow characteristics in 45 recurrent glioblastoma patients before and after treatment with bevacizumab. Perfusion MRI data was processed using a standard single value decomposition (SVD) technique, two block-circulant SVD techniques, and a Bayesian estimation technique. A proportional hazards model showed that patients with a large decrease in relative blood volume (RBV) after treatment had extended overall survival (P = 0.0048). Patients with large pre-treatment relative blood flow (RBF) showed extended progression-free survival (P = 0.0216) and overall survival (P = 0.0112), and patients with a large decrease in RBF following treatment showed extended overall survival (P = 0.0049). These results provide evidence that blood volume and blood flow measurements can be used as biomarkers in patients treated with bevacizumab.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Becker KP, Yu J (2012) Status quo–standard-of-care medical and radiation therapy for glioblastoma. Cancer J 18:12–19

    Article  CAS  PubMed  Google Scholar 

  2. Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol 14(Suppl 5):v1–49

    Article  PubMed Central  PubMed  Google Scholar 

  3. Johnson DR, O’Neill BP (2012) Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 107:359–364

    Article  CAS  PubMed  Google Scholar 

  4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G: radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  CAS  PubMed  Google Scholar 

  5. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994–1998

    Article  CAS  PubMed  Google Scholar 

  6. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367:576–579

    Article  CAS  PubMed  Google Scholar 

  7. Plate KH, Breier G, Risau W (1994) Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol 4:207–218

    Article  CAS  PubMed  Google Scholar 

  8. Young RJ, Gupta A, Shah AD, Graber JJ, Chan TA, Zhang Z, Shi W, Beal K, Omuro AM (2013) MRI perfusion in determining pseudoprogression in patients with glioblastoma. Clin Imaging 37:41–49

    Article  PubMed  Google Scholar 

  9. Server A, Orheim TE, Graff BA, Josefsen R, Kumar T, Nakstad PH (2011) Diagnostic examination performance by using microvascular leakage, cerebral blood volume, and blood flow derived from 3-T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in the differentiation of glioblastoma multiforme and brain metastasis. Neuroradiology 53:319–330

    Article  PubMed  Google Scholar 

  10. Ulmer S, Liess C, Kesari S, Otto N, Straube T, Jansen O (2009) Use of dynamic susceptibility-contrast MRI (DSC-MRI) to assess perfusion changes in the ipsilateral brain parenchyma from glioblastoma. J Neurooncol 91:213–220

    Article  PubMed  Google Scholar 

  11. Young R, Babb J, Law M, Pollack E, Johnson G (2007) Comparison of region-of-interest analysis with three different histogram analysis methods in the determination of perfusion metrics in patients with brain gliomas. J Magn Reson Imaging 26:1053–1063

    Article  PubMed  Google Scholar 

  12. Ulmer S, Hartwigsen G, Riedel C, Jansen O, Mehdorn HM, Nabavi A (2010) Intraoperative dynamic susceptibility contrast MRI (iDSC-MRI) is as reliable as preoperatively acquired perfusion mapping. Neuroimage 49:2158–2162

    Article  PubMed  Google Scholar 

  13. Aronen HJ, Gazit IE, Louis DN, Buchbinder BR, Pardo FS, Weisskoff RM, Harsh GR, Cosgrove GR, Halpern EF, Hochberg FH et al (1994) Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 191:41–51

    Article  CAS  PubMed  Google Scholar 

  14. Maeda M, Itoh S, Kimura H, Iwasaki T, Hayashi N, Yamamoto K, Ishii Y, Kubota T (1993) Tumor vascularity in the brain: evaluation with dynamic susceptibility-contrast MR imaging. Radiology 189:233–238

    Article  CAS  PubMed  Google Scholar 

  15. Boxerman JL, Schmainda KM, Weisskoff RM (2006) Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 27:859–867

    CAS  PubMed  Google Scholar 

  16. Law M, Oh S, Babb JS, Wang E, Inglese M, Zagzag D, Knopp EA, Johnson G (2006) Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging–prediction of patient clinical response. Radiology 238:658–667

    Article  PubMed  Google Scholar 

  17. Calamante F, Gadian DG, Connelly A (2000) Delay and dispersion effects in dynamic susceptibility contrast MRI: simulations using singular value decomposition. Magn Reson Med 44:466–473

    Article  CAS  PubMed  Google Scholar 

  18. Wu O, Ostergaard L, Weisskoff RM, Benner T, Rosen BR, Sorensen AG (2003) Tracer arrival timing-insensitive technique for estimating flow in MR perfusion-weighted imaging using singular value decomposition with a block-circulant deconvolution matrix. Magn Reson Med 50:164–174

    Article  PubMed  Google Scholar 

  19. Liu HL, Pu Y, Liu Y, Nickerson L, Andrews T, Fox PT, Gao JH (1999) Cerebral blood flow measurement by dynamic contrast MRI using singular value decomposition with an adaptive threshold. Magn Reson Med 42:167–172

    Article  CAS  PubMed  Google Scholar 

  20. Boutelier T, Kudo K, Pautot F, Sasaki M (2012) Bayesian hemodynamic parameter estimation by bolus tracking perfusion weighted imaging. IEEE Trans Med Imaging 31:1381–1395

    Article  PubMed  Google Scholar 

  21. Kudo K, Boutelier T, Pautot F, Honjo K, Hu JQ, Wang HB, Shintaku K, Uwano I, Sasaki M (2014) Bayesian analysis of perfusion-weighted imaging to predict infarct volume: comparison with singular value decomposition. Magn Reson Med Sci 13:45–50

    Article  PubMed  Google Scholar 

  22. Sasaki M, Kudo K, Boutelier T, Pautot F, Christensen S, Uwano I, Goodwin J, Higuchi S, Ito K, Yamashita F (2013) Assessment of the accuracy of a Bayesian estimation algorithm for perfusion CT by using a digital phantom. Neuroradiology 55:1197–1203

    Article  PubMed  Google Scholar 

  23. Ellingson BM, Kim HJ, Woodworth DC, Pope WB, Cloughesy JN, Harris RJ, Lai A, Nghiemphu PL, Cloughesy TF (2013) Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology 271:200–210

    Article  PubMed Central  PubMed  Google Scholar 

  24. Mouridsen K, Christensen S, Gyldensted L, Ostergaard L (2006) Automatic selection of arterial input function using cluster analysis. Magn Reson Med 55:524–531

    Article  PubMed  Google Scholar 

  25. Schmainda KM, Prah M, Connelly J, Rand SD, Hoffman RG, Mueller W, Malkin MG (2014) Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. Neuro Oncol 16:880–888

    Article  CAS  PubMed  Google Scholar 

  26. Norris DG (2001) The effects of microscopic tissue parameters on the diffusion weighted magnetic resonance imaging experiment. NMR Biomed 14:77–93

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

National Brain Tumor Society Research Grant (BME, TFC); NIH/NCI 1 R21 CA167354-01 (BME); UCLA Institute for Molecular Medicine Seed Grant (BME); UCLA Radiology Exploratory Research Grant (BME); University of California Cancer Research Coordinating Committee Grant (BME); ACRIN Young Investigator Initiative Grant (BME); Art of the Brain (TFC); Ziering Family Foundation in memory of Sigi Ziering (TFC); Singleton Family Foundation (TFC); and Clarance Klein Fund for Neuro-Oncology (TFC).

Conflict of interest

Drs. Timothy F. Cloughesy, Albert Lai, Whitney Pope, and Benjamin Ellingson are paid consultants for Genentech, Inc., and Hoffman-La Roche, Ltd. Drs. Ellingson and Pope are also a paid consultant for MedQIA, LLC.

Author information

Authors and Affiliations

  1. UCLA Brain Tumor Imaging Laboratory (BTIL), Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, 924 Westwood Blvd., Suite 615, Los Angeles, CA, 90024, USA

    Robert J. Harris, Anthony J. Hardy, Whitney B. Pope & Benjamin M. Ellingson

  2. Department of Biomedical Physics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA

    Robert J. Harris, Anthony J. Hardy & Benjamin M. Ellingson

  3. Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA

    Timothy F. Cloughesy, Phioanh L. Nghiemphu & Albert Lai

  4. Department of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA

    Linda M. Liau

  5. Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California Los Angeles, Los Angeles, CA, USA

    Benjamin M. Ellingson

Authors
  1. Robert J. Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy F. Cloughesy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anthony J. Hardy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Linda M. Liau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Whitney B. Pope
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Phioanh L. Nghiemphu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Albert Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Benjamin M. Ellingson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benjamin M. Ellingson.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Harris, R.J., Cloughesy, T.F., Hardy, A.J. et al. MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab. J Neurooncol 122, 497–505 (2015). https://doi.org/10.1007/s11060-015-1755-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-015-1755-8

Keywords

Search

Navigation